Clinical characteristics of the patients
| Patient number . | Diagnosis . | Age . | Conditioning* . | Rejection prophylaxis† . | GVHD prophylaxis‡ CyA (months) . | GVHD a/c1-153 . |
|---|---|---|---|---|---|---|
| 1 | ALL | 17 | Cy-TBI (12) | TLI, MP | 2 | 0/0 |
| 2 | ALL | 17 | Cy-TBI (12) | TLI, MP | — | 0/0 |
| 3 | AML | 20 | Cy-TBI (13.5) | TLI, MP | 3 | 0/0 |
| 4 | AML | 29 | Cy-TBI (13.5) | TLI, MP | 1 | 0/0 |
| 5 | AML | 35 | Cy-TBI (12) | MP | 2 | 0/0 |
| 6 | AML | 44 | Cy-TBI (12) | — | 3 | 0/0 |
| 7 | AML | 44 | Bu-Cy | MP | 19 | 1/+ |
| 8 | MM | 45 | Cy-TBI (12) | MP | 3 | 1/0 |
| 9 | AML | 48 | Cy-TBI (12) | MP | 5 | 0/0 |
| 10 | AML | 52 | Cy-TBI (12) | MP | 3 | 0/0 |
| Patient number . | Diagnosis . | Age . | Conditioning* . | Rejection prophylaxis† . | GVHD prophylaxis‡ CyA (months) . | GVHD a/c1-153 . |
|---|---|---|---|---|---|---|
| 1 | ALL | 17 | Cy-TBI (12) | TLI, MP | 2 | 0/0 |
| 2 | ALL | 17 | Cy-TBI (12) | TLI, MP | — | 0/0 |
| 3 | AML | 20 | Cy-TBI (13.5) | TLI, MP | 3 | 0/0 |
| 4 | AML | 29 | Cy-TBI (13.5) | TLI, MP | 1 | 0/0 |
| 5 | AML | 35 | Cy-TBI (12) | MP | 2 | 0/0 |
| 6 | AML | 44 | Cy-TBI (12) | — | 3 | 0/0 |
| 7 | AML | 44 | Bu-Cy | MP | 19 | 1/+ |
| 8 | MM | 45 | Cy-TBI (12) | MP | 3 | 1/0 |
| 9 | AML | 48 | Cy-TBI (12) | MP | 5 | 0/0 |
| 10 | AML | 52 | Cy-TBI (12) | MP | 3 | 0/0 |
ALL indicates acute lymphocytic leukemia; AML, acute myelogenous leukemia; MM, multiple myeloma.
Cy indicates cyclophosphamide (120 mg/kg or 200 mg/kg in combination with busulfan (Bu) (4 daily doses of 4 mg/kg body weight, Mesna was used systematically). TBI indicates total body irradiation (Gy given in 6 doses).
TLI indicates total lymphoid irradiation (6 Gy at day −5 and −4); MP indicates methyl prednisolone (4 × 1 g/m2).
GVHD prophylaxis consisted of in vitro T-cell depletion with Campath 1M and Cyclosporin A (CyA) with a trough at 200 ng/mL.
a/c indicates acute/chronic.